Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART)
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana
Virological remission after antiretroviral therapy interruption in female African HIV seroconverters
Do people living with HIV experience greater age advancement than their HIV-negative counterparts?
Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS
Repeat testing of low-level HIV-1 RNA: assay performance and implementation in clinical trials
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa
Kidney Diseases Associated with Human Immunodeficiency Virus Infection
A Randomized, Controlled Trial of a Behavioral Weight Loss Program for HIV-Infected Patients
CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study
Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection
Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection
Antiretroviral therapy for the prevention of HIV-1 transmission
HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy
Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy
Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals
Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis
Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy
CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection
Ongoing HIV Replication Replenishes Viral Reservoirs During Therapy
Incidence and progression of coronary artery calcium in HIV-infected and HIV-uninfected men
Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy
Course and Clinical Significance of CD8+ T-Cell Counts in a Large Cohort of HIV-Infected Individuals
Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients
Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study
Published by François RAFFI
Updated: 1 January, 2017
The prevalence of integrase strand transfer inhibitor (INSTI)–transmitted drug resistance (TDR) may increase with the increasing use of INSTIs.
We analyzed the prevalence of INSTI TDR in the Swiss HIV Cohort Study (2008–2014). 1316 patients had ≥1 genotypic drug resistance test performed for the integrase gene before the first exposure to an INSTI (earliest GRT per patient chosen). Samples retrieved before 2008 were summarized together as a group. We considered drug resistance mutations listed by the IAS–USA in 2015 and differentiated between minor mutations (T66AK, L74 M, E92G, T97A, E138AK, G140AS, and R263K) and major mutations (T66I, E92Q, F121Y, Y143CHR, S147G, Q148HKR, and N155H). To account for potential reversion of TDR mutations in the absence of drug pressure, we performed a subanalysis that included only GRTs from recently infected, treatment-naive patients.
We compared different aspects of the period after the introduction of INSTI (2008–2014) to the periods after introduction of NNRTIs (1998–2004), unboosted PIs (1996–2002), and PI/r (1999–2005).
Treatment failure was defined as ≥1 viral load of ≥ 500 HIV-1 RNA copies/mL (after 180 days of continuous treatment or previous viral suppression) followed by a treatment change or stop.
In 1 of 1316 drug-naive samples (0.1%), a major INSTI TDR mutation was detected (T66I, found in a sample retrieved in 2001). The most common minor mutations, most likely polymorphic, were L74M (17 of 1316 [1.3%]) and T97A (16 of 1316 [1.2%]). Minor mutations were more common in subtype non-B infections as compared to subtype B infections (24 of 466 [5.2%] vs 14 of 850 [1.6%]; P < .001, by the Fisher exact test). Prevalence of minor mutations was stable, although INSTIs were increasingly used. The results were similar when we restricted the analysis to recently infected patients (no major mutation in 303 samples). The low prevalence may be explained by the low number of patients who were potential transmitters of INSTI resistance (between 2008 and 2014, 85 patients experienced a treatment failure on ART including INSTIs in the entire SHCS database).
We showed that this is in contrast to the introduction of previous drug classes, in which more treatment failures with resistant strains occurred and TDR was observed more rapidly. In the 7 years after the introduction of unboosted PIs, PI/r, and NNRTIs, 18.2 times, 5.7 times, and 7.2 times more patients did not respond to the respective ART.
Conclusion : We demonstrated on a population-level that it is possible to avoid TDR to a new drug class for years.